Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The proto-oncogene c-myc encodes a nuclear phosphoprotein, commonly referred to as c-Myc, which is a transcription factor with critical roles in cell cycle progression, apoptosis, cellular transformation, and metabolism. The *MYC* gene is located on human chromosome 8 and regulates the expression of approximately 15% of all genes by binding to enhancer box sequences (E-boxes) in DNA. Deregulation or overexpression leads to oncogenic transformation, frequently observed in many human cancers including lymphomas/leukemias. Constitutive activation disrupts normal control over proliferation/apoptosis/metabolism leading to tumorigenesis.
Dimerization with Max, binding E-boxes, recruitment of HATs/RNA pol II kinases, activation/repression of target genes
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proto-oncogene protein c-myc mRNA (c-Myc).